Cargando…

CDK4/6 inhibitor palbociclib promotes SARS-CoV-2 cell entry by down-regulating SKP2 dependent ACE2 degradation

Coronavirus disease 2019 (COVID-19) outbreak has become a global pandemic. CDK4/6 inhibitor palbociclib was reported to be one of the top-scored repurposed drugs to treat COVID-19. As the receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry, expression level of angiotensin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiao, Yingzi, Yan, Ying, Chang, Le, Ji, Huimin, Sun, Huizhen, Song, Shi, Feng, Kaihao, Nuermaimaiti, Abudulimutailipu, Lu, Zhuoqun, Wang, Lunan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938000/ https://www.ncbi.nlm.nih.gov/pubmed/36806814 http://dx.doi.org/10.1016/j.antiviral.2023.105558

Ejemplares similares

Circulating immune complexes and mutations of HBsAg are associated with the undetectable HBsAg in anti-HBs and HBeAg positive occult hepatitis B virus infection
por: Yan, Ying, et al.
Publicado: (2022)

Role of S protein transmembrane domain mutations in the development of occult hepatitis B virus infection
por: Jiang, Xinyi, et al.
Publicado: (2022)

Nobiletin downregulates the SKP2-p21/p27-CDK2 axis to inhibit tumor progression and shows synergistic effects with palbociclib on renal cell carcinoma
por: Chen, Tingting, et al.
Publicado: (2021)

MYC Modulation around the CDK2/p27/SKP2 Axis
por: Hydbring, Per, et al.
Publicado: (2017)

Degradation of SARS-CoV-2 receptor ACE2 by the E3 ubiquitin ligase Skp2 in lung epithelial cells
por: Wang, Guizhen, et al.
Publicado: (2021)

Cryo-EM structure of SKP1-SKP2-CKS1 in complex with CDK2-cyclin A-p27KIP1
por: Rowland, Rhianna J., et al.
Publicado: (2023)

Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
por: Pandey, Kamal, et al.
Publicado: (2020)

Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity
por: Pogacar, Ziva, et al.
Publicado: (2022)

USP2 is an SKP2 deubiquitylase that stabilizes both SKP2 and its substrates
por: Zhang, Fengwu, et al.
Publicado: (2021)

Discriminative SKP2 Interactions with CDK-Cyclin Complexes Support a Cyclin A-Specific Role in p27KIP1 Degradation
por: Salamina, Marco, et al.
Publicado: (2021)

SARS-CoV-2 down-regulates ACE2 through lysosomal degradation
por: Lu, Yi, et al.
Publicado: (2022)

Down-regulation of Skp2 expression inhibits invasion and lung metastasis in osteosarcoma
por: Zhang, Yidan, et al.
Publicado: (2018)

Skp2 and Skp2B team up against Rb and p53
por: Germain, Doris
Publicado: (2011)

The NUCKS1-SKP2-p21/p27 axis controls S phase entry
por: Hume, Samuel, et al.
Publicado: (2021)

Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy
por: van Aken, Evert S. M., et al.
Publicado: (2021)

Skp2-MacroH2A1-CDK8 axis orchestrates G2/M transition, polyploidy and tumourigenesis
por: Xu, Dazhi, et al.
Publicado: (2015)

Severe Cellular Immunodeficiency Triggered by the CDK4/6 Inhibitor Palbociclib
por: Guillaume, Zoé, et al.
Publicado: (2020)

Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A
por: Martin-Broto, Javier, et al.
Publicado: (2023)

Analysis of the selection of CDK4/6 inhibitors based on experience using palbociclib
por: Kikuchi, Mariko, et al.
Publicado: (2019)

Low seroprevalence of hepatitis delta virus co-infection in hepatitis B virus-infected blood donors in China: A multicenter study
por: Chang, Le, et al.
Publicado: (2022)

USP10 modulates the SKP2/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia
por: Liao, Yuning, et al.
Publicado: (2019)

A Strategy for Screening and Confirmation of HTLV-1/2 Infections in Low-Endemic Areas
por: Ji, Huimin, et al.
Publicado: (2020)

Androgen Suppresses the Proliferation of Androgen Receptor-Positive Castration-Resistant Prostate Cancer Cells via Inhibition of Cdk2, CyclinA, and Skp2
por: Kokontis, John M., et al.
Publicado: (2014)

ACE2: The Major Cell Entry Receptor for SARS-CoV-2
por: Scialo, Filippo, et al.
Publicado: (2020)

SARS-CoV-2 Entry: At the Crossroads of CD147 and ACE2
por: Fenizia, Claudio, et al.
Publicado: (2021)

SARS-CoV-2 cell entry beyond the ACE2 receptor
por: Alipoor, Shamila D., et al.
Publicado: (2022)

Curcumin suppresses cell growth and invasion and induces apoptosis by down-regulation of Skp2 pathway in glioma cells
por: Wang, Lixia, et al.
Publicado: (2015)

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
por: Braal, C. Louwrens, et al.
Publicado: (2020)

Novel therapeutic strategy for melanoma based on albendazole and the CDK4/6 inhibitor palbociclib
por: Zhu, Lin, et al.
Publicado: (2022)

The Drosophila F-box protein dSkp2 regulates cell proliferation by targeting Dacapo for degradation
por: Dui, Wen, et al.
Publicado: (2013)

Menin Upregulates FOXO1 Protein Stability by Repressing Skp2-Mediated Degradation in β Cells
por: Jiang, Zongzhe, et al.
Publicado: (2019)

Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
por: Lu, Janice
Publicado: (2015)

Correction: Androgen Suppresses the Proliferation of Androgen Receptor-Positive Castration-Resistant Prostate Cancer Cells via Inhibition of Cdk2, CyclinA, and Skp2
Publicado: (2014)

Inhibition of the CDK2 and Cyclin A complex leads to autophagic degradation of CDK2 in cancer cells
por: Zhang, Jiawei, et al.
Publicado: (2022)

Glycyrrhizin Inhibits SARS-CoV-2 Entry into Cells by Targeting ACE2
por: He, Ming-Feng, et al.
Publicado: (2022)

Nifuroxazide boosts the anticancer efficacy of palbociclib-induced senescence by dual inhibition of STAT3 and CDK2 in triple-negative breast cancer
por: Wang, Xianzhe, et al.
Publicado: (2023)

Skp2 modulates proliferation, senescence and tumorigenesis of glioma
por: Wu, Juan, et al.
Publicado: (2020)

Emerging Roles of SKP2 in Cancer Drug Resistance
por: Wu, Ting, et al.
Publicado: (2021)

The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells
por: Shapira, Ma'anit, et al.
Publicado: (2006)

p107 inhibits G1 to S phase progression by down-regulating expression of the F-box protein Skp2
por: Rodier, Geneviève, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_5bj3mi98koklbcavj92oam2ror